These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16001162)

  • 1. Immunotherapy in chronic lymphocytic leukemia.
    Bruserud Ø; McCormack E; Gjertsen BT
    Cancer Immunol Immunother; 2006 Feb; 55(2):185-7. PubMed ID: 16001162
    [No Abstract]   [Full Text] [Related]  

  • 2. Third symposium on new aspects of biology and treatment of B chronic lymphocytic leukemia.
    Berrebi A
    Isr Med Assoc J; 2004 Sep; 6(9):573-5. PubMed ID: 15373325
    [No Abstract]   [Full Text] [Related]  

  • 3. CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.
    Hay KA; Turtle CJ
    Immunotherapy; 2018 Feb; 10(4):251-254. PubMed ID: 29421980
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
    Porter DL
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
    [No Abstract]   [Full Text] [Related]  

  • 5. An update on current and prospective immunotherapies for chronic lymphocytic leukemia.
    Emole JN; Locke FL; Pinilla-Ibarz J
    Immunotherapy; 2015; 7(4):455-66. PubMed ID: 25917633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications.
    Riches JC; Gribben JG
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):207-35. PubMed ID: 23561470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.
    Foster AE; Brenner MK; Dotti G
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):375-89. PubMed ID: 18790444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impairments in immune cell function in B cell chronic lymphocytic leukemia.
    Bartik MM; Welker D; Kay NE
    Semin Oncol; 1998 Feb; 25(1):27-33. PubMed ID: 9482524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
    Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
    Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.
    Shah N; Rezvani K; Hosing C; Kebriaei P; Wierda W; Cooper L; Shpall E
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl(Suppl):S18-22. PubMed ID: 25486950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine- and immune-based therapy in chronic lymphocytic leukemia.
    Le Dieu R; Gribben J
    Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
    Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
    Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia.
    Riches JC; Gribben JG
    Discov Med; 2013 Dec; 16(90):295-302. PubMed ID: 24333409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.
    Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Osterborg A; Mellstedt H
    Leukemia; 2004 Nov; 18(11):1810-5. PubMed ID: 15385926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-idiotype tumor vaccines.
    Bhattacharya-Chatterjee M; Kohler H
    Adv Exp Med Biol; 1989; 251():113-27. PubMed ID: 2692424
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological leukemia treatment shows breakthrough potential.
    Mayo Clin Health Lett; 2011 Dec; 29(12):4. PubMed ID: 22295296
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia.
    Tolba KA; Bowers WJ; Hilchey SP; Halterman MW; Howard DF; Giuliano RE; Federoff HJ; Rosenblatt JD
    Blood; 2001 Jul; 98(2):287-95. PubMed ID: 11435295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.
    Spaner DE; Hammond C; Mena J; Foden C; Deabreu A
    Cancer Immunol Immunother; 2005 Jul; 54(7):635-46. PubMed ID: 15918075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.